FDA Clearance obtained for a First in Human Clinical Study for Stage III/IV Ovarian Cancer Treatment with Autologous Vaccine Therapy, Innocell™ March 12, 2024
IMBRUVICA® (ibrutinib) Label expanded in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications March 12, 2024
Application submitted to the EMA for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma March 12, 2024
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous NSCLC or HR+, HER2 Negative Breast Cancer March 12, 2024
U.S. FDA Approves Opdivo + Cisplatin + Gemcitabine for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma March 12, 2024
RYBREVANT® (amivantamab-vmjw) + Chemo gets FDA approval for First-line Treatment of Patients With NSCLC with EGFR Exon 20 Insertion Mutations March 12, 2024
